Ivabradine, coronary heart disease, and heart failure: time for reappraisal
- PMID: 25301354
- DOI: 10.1007/s11883-014-0463-8
Ivabradine, coronary heart disease, and heart failure: time for reappraisal
Abstract
Ivabradine is generally considered to be a safe drug with well-established and substantial benefits. Nevertheless, recently published results from the SIGNIFY trial suggest that ivabradine has rather inconsistent effects on cardiovascular outcomes. In addition, careful examination of all available data from ivabradine trials reveals signals of harm that have not yet been appropriately addressed, including a markedly increased incidence of atrial fibrillation and increased risk of cardiovascular events in patients with heart rates below 70 bpm. These concerns warrant consideration, since they could have implications for the future use of ivabradine.
Comment on
-
Ivabradine in stable coronary artery disease without clinical heart failure.N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31. N Engl J Med. 2014. PMID: 25176136 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical